Concurrent Daily Cisplatin and High-Dose Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer
| Autor: | Meike W. van Hoek, Mia G. J. Koolen, Apollonia L. J. Uitterhoeve, Jan Wiersma, Jouke T. Annema, Hein J. Verberne, Coen R.N. Rasch, Rob M. van Os, Edith M.T. Dieleman, Judit A. Adam, Caro C.E. Koning, M.W. Kolff |
|---|---|
| Přispěvatelé: | Radiotherapy, CCA - Cancer Treatment and Quality of Life, Nuclear Medicine, Radiology and Nuclear Medicine, Amsterdam Cardiovascular Sciences, CCA - Imaging and biomarkers, Pulmonology |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lung Neoplasms Time Factors Gastroenterology Disease-Free Survival 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Fluorodeoxyglucose F18 Recurrence Carcinoma Non-Small-Cell Lung Positron Emission Tomography Computed Tomography Internal medicine Carcinoma medicine Humans Radiology Nuclear Medicine and imaging Neoplasm Metastasis Stage (cooking) Survival rate Lymph node Aged Retrospective Studies Pneumonitis Aged 80 and over Radiation business.industry Hazard ratio Dose fractionation Chemoradiotherapy Middle Aged Prognosis medicine.disease Combined Modality Therapy Treatment Outcome medicine.anatomical_structure Oncology Lymphatic Metastasis 030220 oncology & carcinogenesis Female Dose Fractionation Radiation Cisplatin business |
| Zdroj: | International Journal of Radiation Oncology-Biology-Physics, 102(3), 543-551. ELSEVIER SCIENCE INC International journal of radiation oncology, biology, physics, 102(3), 543-551. Elsevier Inc. |
| ISSN: | 0360-3016 |
| Popis: | Purpose: The purpose of this study was to determine survival, local and distant control, toxicity, and prognostic factors in patients with stage III non-small cell lung cancer (NSCLC) treated with concurrent chemoradiation therapy (CCRT).Methods and Materials: Consecutive patients with stage IIIA and IIIB NSCLC (N = 154) staged with (18) F-fluorodeoxyglucose positron emission tomography/ computed tomography were retrospectively selected (2005-2015). CCRT consisted of daily low-dose cisplatin (6 mg/m(2)) combined with 24 fractions of 2.75 Gy to a total dose of 66 Gy.Results: During a median follow-up period of 22 months (range, 1-92 months) the median overall survival was 36 months. The 1-, 2-, 3-, and 5-year survival rates were 79% (95% confidence interval [CI], 73%-86%), 61% (95% CI, 54%-70%), 52% (95% CI, 43%-60%), and 40% (95% CI, 31%-51%), respectively. The local relapse-free survival at 5 years was 55% (95% CI, 44%-69%). Metastasis-free survival at 5 years was 53% (95% CI, 44%-65%). The incidence of severe gastrointestinal disorders (grade 3-5) was 11%, among which grade 3 radiation esophagitis was 8.4%. The incidence of severe respiratory, thoracic, and mediastinal disorders (grade 3-5) was 8.4%, among which grade 3 radiation pneumonitis was 1.3%. Predictors of overall survival were lymph node gross tumor volume (GTV) (hazard ratio [HR], 1.007; 95% CI, 1.000-1.012) and sex (HR, 0.500; 95% CI, 0.320-0.870) in favor of women. Although lymph node GTV was a predictor of treatment toxicity (HR, 1.010; 95% CI, 1.000-1.013), tumor GTV was the predictor for distant metastasis during follow-up (HR, 1.002; 95% CI, 1.0011.003).Conclusions: CCRT with daily low-dose cisplatin for locally advanced stage III NSCLC resulted in promising overall survival (3-year survival rate of 52% and 5-year survival rate of 40%) with low toxicity. Lymph node GTV, tumor GTV, and sex were predictors of overall survival, treatment toxicity, and distant metastasis. (C) 2018 The Authors. Published by Elsevier Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|